Skip to main content
SpringerLink
Log in

Venetoclax in CLL: better outcomes, lower cost

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Alsaid N, et al. Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p). 54th Annual Meeting of the American Society of Clinical Oncology : abstr. 7527, 1 Jun 2018. Available from: URL: http://abstracts.asco.org/214/AbstView_214_218741.html

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Venetoclax in CLL: better outcomes, lower cost. PharmacoEcon Outcomes News 806, 34 (2018). https://doi.org/10.1007/s40274-018-5077-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5077-x

Search

Navigation